Clinical Review: Semaglutide, Fatigue, and Related Physiological Effects

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

Introduction

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist and a synthetic analogue of human GLP-1. It is recognized for its ability to lower blood glucose, reduce body weight, and promote pancreatic beta-cell growth. Weight reduction with semaglutide is achieved through multiple mechanisms:

• Appetite regulation: Diminishes hunger by acting centrally and by delaying gastric emptying.
• Metabolic shift: Improves insulin sensitivity and reduces fat storage.
• Behavioral influence: Decreases cravings and influences feeding behavior.

Clinical data show that after 20 weeks of treatment, semaglutide can lead to significant weight reduction, averaging about 8% compared to weight gain in placebo groups. More intensive treatment regimens have demonstrated reductions of up to 16% over 2–3 months. For obesity management, semaglutide is typically given as a once-weekly injection, differing from the dosing schedules used in type 2 diabetes.

Fatigue and Semaglutide Use

Frequency and Severity

Clinical trials suggest that semaglutide can cause fatigue, though the incidence varies across formulations. Fatigue has been reported in approximately 0.4% to 11% of individuals, depending on the preparation studied. Most cases are mild and self-limiting, resolving within one to two months of continued use. Some individuals report fatigue primarily on the day of injection, which can often be minimized by timing the dose around natural sleep cycles.

Mechanisms of Fatigue

The most likely cause is the calorie deficit produced by appetite suppression. Central GLP-1 signaling may also contribute, as endogenous GLP-1 release after meals is associated with postprandial sleepiness. This biphasic release pattern, particularly the later phase occurring 30–60 minutes after eating, is thought to play a role in meal-induced fatigue.

Interestingly, GLP-1 receptor agonists are currently under investigation for their potential role in modulating sleep quality, particularly non-REM sleep, which may explain early observations linking semaglutide with improved sleep-related outcomes.

Management Strategies

Lifestyle modifications—such as balanced nutrition, regular activity, and minimizing alcohol use—are generally effective in reducing fatigue. In most cases, no medical intervention is required.

Alterations in Taste and Food Preferences

Evidence suggests that semaglutide influences taste perception and food preference. Reports from both preclinical models and human studies indicate reduced desire for high-fat, high-sugar foods. Many patients describe these foods as less appealing, which supports adherence to healthier dietary patterns.

This effect appears to arise from central nervous system pathways. GLP-1 is present in neural circuits transmitting gustatory information, indicating that semaglutide likely influences taste signaling directly at the brain level.

A similar reduction in alcohol craving has also been documented. Experimental studies in rodents confirm that semaglutide can reduce binge-like alcohol consumption and alter neurotransmission in brain regions regulating reward and intake behaviors. These findings support ongoing research into GLP-1 receptor agonists as potential therapeutic options for alcohol use disorder.

Gastrointestinal Adverse Effects

Nausea, vomiting, and constipation are among the most common adverse effects of semaglutide. Approximately 20% of patients experience nausea, with smaller percentages reporting vomiting or constipation.

These effects result from delayed gastric emptying, which enhances satiety but can cause discomfort in susceptible individuals. Gradual dose escalation, smaller meal portions, reduced dietary fat intake, avoidance of alcohol, and adequate hydration can help mitigate gastrointestinal symptoms. Most individuals adapt to therapy with time.

Neurological and Sleep-Related Observations

Some patients report vivid dreams while on semaglutide. This is consistent with the widespread distribution of GLP-1 receptors within the central nervous system.

GLP-1 analogues have also demonstrated potential neuroprotective effects. In experimental models, they appear to reduce amyloid-beta accumulation and support neuronal health, suggesting a possible role in conditions such as Alzheimer’s disease. Further studies are needed to clarify these mechanisms.

In addition, semaglutide may influence PPG neurons, which are implicated in energy balance and anxiety-related circuitry. This could explain links between semaglutide use, heightened stress responses, and altered dream activity.

Clinical Summary

Semaglutide is an effective GLP-1 receptor agonist with well-documented benefits for weight reduction and glycemic control. While generally well tolerated, it can cause fatigue, altered taste perception, gastrointestinal symptoms, and in some cases, changes in dream patterns.

• Fatigue: Usually transient, related to caloric restriction and GLP-1 signaling.
• Taste changes: Reduction in preference for fatty and sugary foods, as well as alcohol.
• Gastrointestinal effects: Common but manageable through lifestyle adjustments and dose titration.
• Neurological effects: Possible impact on sleep and cognitive function, under active investigation.

In most patients, the benefits of semaglutide outweigh the risks. Careful dose initiation and gradual escalation help minimize adverse events while maximizing clinical outcomes.

REFERENCES

1. Baggio LL, Drucker DJ. Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight. J Clin Invest. 2014;124(10):4223–4226. doi:10.1172/JCI78371.
2. Chen Z, Zhong C. Decoding Alzheimer’s disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Prog Neurobiol. 2013;108:21–43. doi:10.1016/j.pneurobio.2013.06.004.
3. Sun Y, et al. Metabolism: A Novel Shared Link between Diabetes Mellitus and Alzheimer’s Disease. J Diabetes Res. 2020;4981814. doi:10.1155/2020/4981814.
4. Leclerc M, et al. Cerebrovascular insulin receptors are defective in Alzheimer’s disease. Brain. 2022;146(1):75–90. doi:10.1093/brain/awac309.
5. Ferrari F, Moretti A, Villa RF. Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives. Pharmacol Ther. 2022;239:108277. doi:10.1016/j.pharmthera.2022.108277.
6. McLean BA, et al. Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation. Endocr Rev. 2020;42(2):101–132. doi:10.1210/endrev/bnaa032.
8. Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414–1425. doi:10.1001/jama.2021.3224.
9. Ghusn W, et al. Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity. JAMA Netw Open. 2022;5(9):e2231982. doi:10.1001/jamanetworkopen.2022.31982.
10. Gilbert MP, Pratley RE. GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials. Front Endocrinol. 2020;11:178. doi:10.3389/fendo.2020.00178.
11. Jensterle M, Rizzo M, Janez A. Glucagon-Like Peptide 1 and Taste Perception: From Molecular Mechanisms to Potential Clinical Implications. Int J Mol Sci. 2021;22(2):902. doi:10.3390/ijms22020902.

Product available for research use only: